Ground-breaking clinical study on Tocomin SupraBio shows improved fatty liver disease

A ground-breaking human clinical study shows supplementation with patented and bio-enhanced natural full spectrum palm tocotrienol complex (Tocomin SupraBio®) at 400mg daily for one year improves fatty liver in non-alcoholic fatty liver disease (NAFLD).

NAFLD often coexists with metabolic syndrome especially type 2 diabetes and obesity. It is reported to be an independent risk factor for cardiovascular disease and affects approximately 30% of the population in Western countries. Recently, the University of Hong Kong reported that a staggering 40% of healthy Hong Kong population have non-alcoholic fatty liver disease, with majority of them not aware of the condition.